COMPANY

TriSalus Life Sciences

HQ: Westminster, CO source · trisaluslifesci.com ↗ · Mountain

FDA-cleared device company Clinical Phase 2

3 open jobs · last seen Oct 23, 2026 · 4 sources

Keywords: oncology tumors uveal melanoma Hepatocellular Carcinoma Intrahepatic Cholangiocarcinoma Metastatic Uveal Melanoma in the Liver Locally Advanced Pancreatic Adenocarcinoma SD-101

Profile checked Oct 10, 2026

3Open jobs $40.0MRaised (2 yrs)3Trials (company is sponsor)

Hiring

Title	Location (from posting)	Employer posted	First seen
Sr Regional Oncology Business Manager, Nashville	REMOTE, US	Oct 21, 2026	Oct 22, 2026
Engineering Technician	TriSalus Life Sciences, Westminster, CO, US	Sep 10, 2026	Oct 11, 2026
Sr. Manufacturing/Process Engineer	Westminster, CO, US	Jun 30, 2026	Oct 11, 2026

See all 3 jobs

Timeline

Feb 20, 2026 Raise Follow-on offering: $40M (total, as published), announced Feb 20, 2026. Source: SEC filing. source ↗
Mar 1, 2023 Trial start Phase 1: Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma source ↗
Mar 2, 2022 Trial start Phase 1/Phase 2: Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors source ↗
Aug 2, 2021 Trial start Phase 1: Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma source ↗

Upcoming milestones

2027-09 (ESTIMATED) · Phase 1 · Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma · NCT05607953

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $40.0M. Last 2 years.

Feb 20, 2026 Follow-on offering: $40M (total, as published), announced Feb 20, 2026. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT05220722	Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors	Phase 1/Phase 2	Terminated	Mar 2, 2022	Jul 31, 2024 (actual)
NCT04935229	Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma	Phase 1	Terminated	Aug 2, 2021	Jul 17, 2024 (actual)
NCT05607953	Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma	Phase 1	Active, not recruiting	Mar 1, 2023	2027-09 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2025-05-08 Raise Private raise (SEC Form D): $22.0M sold; issuer “TriSalus Life Sciences, Inc.”. Verified from the SEC filing. SEC filing ↗
2024-12-30 Raise Private raise (SEC Form D): $1000K sold; issuer “TriSalus Life Sciences, Inc.”. Verified from the SEC filing. SEC filing ↗
InvestorListed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗

Open jobs 3

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Sr Regional Oncology Business Manager, Nashville	REMOTE, US	Oct 21, 2026	Oct 22, 2026	Not stated
Engineering Technician	TriSalus Life Sciences, Westminster, CO, US	Sep 10, 2026	Oct 11, 2026	Entry
Sr. Manufacturing/Process Engineer	Westminster, CO, US	Jun 30, 2026	Oct 11, 2026	Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at TriSalus Life Sciences on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12